Chylomicron metabolism is markedly altered in systemic lupus erythematosus.
OBJECTIVE
To verify the in vivo status of chylomicron metabolism in systemic lupus erythematosus (SLE) since there is a high incidence of atherosclerosis in this disease and chylomicrons may have an important role in atherogenesis.


METHODS
A chylomicron-like emulsion labeled with 14C-cholesteryl esters and 3H-triglycerides was injected intravenously into 10 female patients with inactive SLE and 10 healthy age- and sex-matched control subjects to determine the plasma kinetics of the emulsion lipids from consecutive plasma samples taken at regular intervals for 1 hour. Lipolytic activity was determined in vitro after incubation of the labeled emulsion with postheparin plasma.


RESULTS
The decay curves for the emulsion were markedly slowed in SLE. Chylomicron lipolysis, indicated by the fractional clearance rate (FCR) of emulsion 3H-triglyceride, was 2-fold smaller in SLE patients than in controls (mean +/- SD 0.023 +/- 0.011 versus 0.047 +/-0.015 minute(-1); P = 0.010). Chylomicron removal, indicated by emulsion 14C-cholesteryl ester FCR, was 3-fold smaller in SLE patients than in controls (0.007 +/-0.007 versus 0.023 +/- 0.011 minute(-1); P = 0.009). In vitro lipolysis in SLE patients was nearly half that of the controls (mean +/- SD 10,199 +/- 2,959 versus 6,598 +/-2,215; P = 0.014). Higher levels of very-low-density lipoprotein cholesterol and triglycerides and lower levels of high-density lipoprotein cholesterol and apolipoprotein A-I were also observed in the SLE patients.


CONCLUSIONS
SLE patients have disturbances in chylomicron metabolism that are characterized by decreased lipolysis and chylomicron remnant removal from the plasma. This finding, together with other alterations in lipid profiles that were confirmed in the present study, is largely accountable for the accelerated atherosclerotic process of the disease.
Borba
E F
EF
University of São Paulo, Brazil.
Bonfá
E
E
Vinagre
C G
CG
Ramires
J A
JA
Maranhão
R C
RC
D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D015992:Body Mass Index; D002250:Carbon Radioisotopes; D002788:Cholesterol Esters / Q000097:blood; D002914:Chylomicrons / Q000378:metabolism*; D004655:Emulsions / Q000378:metabolism; D005260:Female; D006493:Heparin / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008055:Lipids / Q000097:blood; D008066:Lipolysis; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism*; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014316:Tritium
D001053:Apolipoproteins; D002250:Carbon Radioisotopes; D002788:Cholesterol Esters; D002914:Chylomicrons; D004655:Emulsions; D008055:Lipids; D014280:Triglycerides; D014316:Tritium; D006493:Heparin